D. W. Branch, M. Gibson, and R. M. Silver, Clinical practice. Recurrent miscarriage, N Engl J Med, vol.363, pp.1740-1747, 2010.

M. Ogasawara, K. Aoki, and S. Okada, Embryonic karyotype of abortuses in relation to the number of previous miscarriages, Fertil Steril, vol.73, pp.300-304, 2000.

E. Rey, S. R. Kahn, and M. David, Thrombophilic disorders and fetal loss: a meta-analysis, Lancet, vol.361, pp.901-909, 2003.

B. Isermann, R. Sood, and R. Pawlinski, The thrombomodulin-protein C system is essential for the maintenance of pregnancy, Nat. Med, vol.9, pp.331-338, 2003.

W. Li, X. Zheng, and J. M. Gu, Extraembryonic expression of EPCR is essential for embryonic viability, Blood, vol.106, pp.2716-2738, 2005.

I. Laude, C. Rongières-bertrand, and C. Boyer-neumann, Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight, Thromb Haemost, vol.85, pp.18-21, 2001.

R. Rai, E. Tuddenham, and M. Backos, whole-blood haemostasis and recurrent miscarriage, Hum Reprod, vol.18, pp.2540-2543, 2003.

L. De-saint-martin, J. Duchemin, and C. Bohec, Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss, Fertil Steril, vol.95, pp.1813-1818, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00721941

E. Pasquier, L. De-saint-martin, and C. Bohec, Unexplained pregnancy loss: a marker of basal endothelial dysfunction?, Fertil Steril, vol.100, pp.1013-1020, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00935486

E. Kharazmi, L. Dossus, and S. Rohrmann, Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg), Heart, vol.97, pp.49-54, 2011.

S. P. Kaandorp, M. Goddijn, and J. A. Van-der-post, Aspirin plus heparin or aspirin alone in women with recurrent miscarriage, N Engl J Med, vol.362, pp.1586-96, 2010.

P. Clark, I. D. Walker, and P. Langhorne, SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage, Blood, vol.115, pp.4162-4169, 2010.

J. Visser, V. M. Ulander, and F. M. Helmerhorst, Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial, Thromb Haemost, vol.105, pp.295-301, 2011.

E. Pasquier, L. De-saint-martin, and C. Bohec, Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial, Blood, vol.125, pp.2200-2205, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01275892

M. A. Rodger, W. M. Hague, and J. Kingdom, Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial, 16. van den Boogaard E, vol.384, pp.605-624, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01258557

R. Rai and L. Regan, Recurrent miscarriage, Lancet, vol.368, pp.601-612, 2006.

A. S. Figueiredo and A. Schumacher, The T helper type 17/regulatory T cell paradigm in pregnancy, Immunology, vol.148, pp.13-21, 2016.

X. Kang, X. Zhang, and Z. Liu, Excessive TLR9 signaling contributes to the pathogenesis of spontaneous abortion through impairment of Treg cell survival by activation of Caspase 8/3, Int Immunopharmacol, vol.29, pp.285-92, 2015.

T. F. Porter, Y. Lacoursiere, and J. R. Scott, Immunotherapy for recurrent miscarriage, Cochrane Database Syst Rev, vol.2, p.112, 2006.

P. Egerup, J. Lindschou, and C. Gluud, The effects of intravenous immunoglobulins in women with recurrent miscarriages: a systematic review of randomised trials with meta-analyses and trial sequential analyses including individual patient data, PLoS One, vol.10, p.141588, 2015.

A. W. Tang, Z. Alfirevic, and M. A. Turner, A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant, Hum Reprod, vol.28, pp.1743-52, 2013.

H. S. Liddell, N. S. Pattison, and A. Zanderigo, Recurrent miscarriage--outcome after supportive care in early pregnancy, Aust N Z J Obstet Gynaecol, vol.31, pp.320-322, 1991.

S. Miyakis, M. D. Lockshin, and T. Atsumi, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, vol.4, pp.295-306, 2006.

C. A. Laskin, K. A. Spitzer, and C. A. Clark, Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial, J Rheumatol, vol.36, pp.279-87, 2009.

D. J. Wallace, Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?, Arthritis Rheum, vol.30, pp.1435-1441, 1987.

E. Johansson, K. Forsberg, and H. Johnsson, Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement, Haemostasis, vol.10, pp.89-96, 1981.

R. Johnson and J. Charnley, Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty, Clin Orthop Relat Res, vol.144, pp.174-181, 1979.

A. E. Carter and R. Eban, Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate, Br Med J, vol.3, pp.94-99, 1974.

T. K. Wu, M. J. Tsapogas, and F. R. Jordan, Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin, Surg Gynecol Obstet, vol.145, pp.714-722, 1977.

G. Ruiz-irastorza, M. V. Egurbide, and J. I. Pijoan, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus, Lupus, vol.15, pp.577-83, 2006.

M. G. Tektonidou, K. Laskari, and D. B. Panagiotakos, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Rheum, vol.61, pp.29-36, 2009.

H. Jung, R. Bobba, and J. Su, The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis Rheum, vol.62, pp.863-871, 2010.

M. H. Edwards, S. Pierangeli, and X. Liu, Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice, Circulation, vol.96, pp.4380-4384, 1997.

A. Schmidt-tanguy, J. Voswinkel, and D. Henrion, Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients, J Thromb Haemost, vol.11, issue.9, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02347272

B. P. Madow, Use of antimalarial drugs as "desludging" agents in vascular disease processes, J Am Med Assoc, vol.172, pp.1630-1633, 1960.

E. Ernst, M. Rose, and R. Lee, Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect, Pharmatherapeutica, vol.4, pp.48-52, 1984.

A. E. Carter, R. Eban, and R. D. Perrett, Prevention of postoperative deep venous thrombosis and pulmonary embolism, Br Med J, vol.1, pp.312-316, 1971.

R. G. Espinola, S. S. Pierangeli, and A. E. Gharavi, Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies, Thromb Haemost, vol.87, pp.518-540, 2002.

J. H. Rand, X. X. Wu, and A. S. Quinn, Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers, Blood, vol.112, pp.1687-95, 2008.

H. C. Gerstein, K. E. Thorpe, and D. W. Taylor, The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial, Diabetes Res Clin Pract, vol.55, pp.209-228, 2002.

M. Petri, C. Lakatta, and L. Magder, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis, Am J Med, vol.96, pp.254-263, 1994.

A. Virdis, C. Tani, and E. Duranti, Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus, Arthritis Res Ther, vol.17, p.277, 2015.

N. T. Le, Y. Takei, and Y. Izawa-ishizawa, Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents, J Immunol, vol.193, pp.3803-3818, 2014.

R. Lafyatis, M. York, and A. Marshak-rothstein, Antimalarial agents: closing the gate on Toll-like receptors?, Arthritis Rheum, vol.54, pp.3068-70, 2006.

D. Kyburz, F. Brentano, and S. Gay, Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling, Nat Clin Pract Rheumatol, vol.2, pp.458-467, 2006.

A. Kuznik, M. Bencina, and U. Svajger, Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines, J Immunol, vol.186, pp.4794-804, 2011.

I. C. Bygbjerg, M. Svenson, and T. G. Theander, Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes, Int J Immunopharmacol, vol.9, pp.513-522, 1987.

. Van-den-borne, . Be, B. A. Dijkmans, and H. H. De-rooij, Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells, J Rheumatol, vol.24, pp.55-60, 1997.

S. M. Weber and S. M. Levitz, Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism, J Immunol, vol.165, pp.1534-1574, 2000.

A. Broder and C. Putterman, Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus, J Rheumatol, vol.40, pp.30-33, 2013.

E. Raschi, M. O. Borghi, and C. Grossi, Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome, Lupus, vol.17, pp.938-981, 2008.

Y. Döring, J. Hurst, and M. Lorenz, Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8, Immunobiology, vol.215, pp.230-271, 2010.

, , 2019.

J. Berman, G. Girardi, and J. E. Salmon, TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss, J Immunol, vol.174, pp.485-90, 2005.

Y. C. Kaplan, J. Ozsarfati, and C. Nickel, Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis, Br J Clin Pharmacol, vol.81, pp.835-883, 2016.

C. Götestam-skorpen, M. Hoeltzenbein, and A. Tincani, The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation, Ann Rheum Dis, vol.75, pp.795-810, 2016.

N. Tarfaoui, E. Autret-leca, and S. Mazjoub,

, Therapie, vol.68, pp.43-50, 2013.

S. A. Brigham, C. Conlon, and R. G. Farquharson, A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage, Hum Reprod, vol.14, pp.2868-71, 1999.

A. Mekinian, M. G. Lazzaroni, and A. Kuzenko, The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a european multicenter retrospective study, Autoimmun Rev, vol.14, pp.498-502, 2015.

, , 2019.